Title: Human Gut Bacteria Tailor Extracellular Vesicle Cargo for the Breakdown of Diet- and host-derived glycans
Dr. Feldman obtained his Ph.D. at the University of Buenos Aires, Argentina, under the supervision of Dr. Armando Parodi. After completing his postdoctoral training in Guy Cornelis and Markus Aebi labs in Switzerland, he joined the University of Alberta, in Edmonton, Canada, as an assistant professor. In 2015 he moved to the Department of Microbiology at the Washington University School of Medicine in St Louis, USA. The Feldman lab is interested in microbial glycobiology and bacterial pathogenesis. Dr. Feldman has pioneered the field of bacterial glycoengineering, which is a promising approach for the generation of novel bioconjugate vaccines. He has co-founded two companies (VaxAlta and Omniose) in this area. He is a world leader in studying the human pathogen Acinetobacter baumannii and the biogenesis of bacterial extracellular vesicles. Dr. Feldman is a fellow of the American Academy of Microbiology.
Professor Yasuhiro Kajihara received his Ph.D. from the Tokyo Institute of Technology in 1993. He spent two years at the Life Science Research Laboratory of Japan Tobacco Inc. as a postdoctoral fellow. In 1995 he joined Yokohama City University as an assistant professor and was then promoted to associate professor in 2001 and full professor in 2007. At YCU, he developed synthetic methods for oligosaccharides and glycoproteins. In 2009, he moved to the Department of Chemistry at Osaka University. He studies new synthetic methods of glycoproteins in order to understand how oligosaccharides regulate protein functions.
Title: A functional study of O-GlcNAcylation on RNA binding protein RBM14
Professor Won Ho Yang received his Ph.D. from Yonsei University, Seoul, Korea, in 2007. After postdoctoral work in the laboratory of Professor Jamey Marth at the UC Santa Barbara, he joined the Department of Systems Biology, Glycosylation Network Research Center, at Yonsei University as an Assistant Professor in 2019. His research interest is understanding the function of protein glycosylation in normal physiology and the pathogenesis of the disease.
Title: Desialylation GlycoSwitch to Acutely Control Endocytosis
Professor Ludger Johannes is Research Director (DRE) at INSERM. He is a member of the Studienstiftung des Deutschen Volkes (German organization of the academically gifted), Boehringer Ingelheim Fonds, European Molecular Biology Organization (EMBO), and German Academy of Science — Leopoldina. At Institut Curie, he has been heading since 2001 the Traffic, Signaling, and Delivery Team, member of the excellence initiative Cell(n)Scale. Since January 2014, he has directed the Cellular and Chemical Biology unit. His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking. The Johannes team has discovered the membrane trafficking interface between early endosomes and the Golgi apparatus, and demonstrated that lectin-induced glycolipid reorganization acts as a driving force in clathrin-independent endocytosis (termed the GlycoLipid-Lectin / GL-Lect hypothesis). The studies of the Johannes team have been published in highly visible international journals, including Cell and Nature. Between 2014-2020, he was the holder of an ERC advanced grant. He also aims at exploiting the discoveries of his team for the development of innovative cancer therapy strategies using the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy.
Title: Exploring Glycosylation-dependent Pathways as Modulators of Intestinal Inflammation
Dr. Mariño received her Ph.D. in Chemistry from the University of Buenos Aires. She continued her training as a postdoc at the University of Dundee (Scotland, UK) and later, at the National Institute for Bioprocessing, Research, and Training (Dublin, Ireland), integrating her chemical vision of carbohydrates into the biochemistry of glycans and the structural analysis of glycoconjugates in physiological and pathological contexts. After relocating to Argentina, she established the Functional and Molecular Glycomics Lab (Institute of Biology and Experimental Medicine). As an Independent Researcher at CONICET, she focuses on how inflammatory conditions could alter the glycome in inflammatory bowel diseases and colorectal cancer and whether these changes can promote the establishment of altered lectin-glycan interactions and, in doing so, influence the immune response. Her goal is to capitalize on glycoimmunological mechanisms that could potentially re-wire immune circuits in these pathologies, providing novel opportunities for translational medicine.
Based on her glycoanalytical experience, she also offers consultancies on glycosylation analysis to the Latin American Life Sciences Industry. She received several prizes for her work, including the "Carlos B. Udaondo" award from the National Academy of Medicine (2019). She is the current National Representative for Argentina at the International Glycoconjugate Organization.
Title: An interface is worth a thousand pictures: An integrated systems approach to glycobiology
Dr. Daniel Bojar is a tenure-track assistant professor at the Wallenberg Centre for Molecular and Translational Medicine & the Department of Chemistry and Molecular Biology at the University of Gothenburg in Sweden, focusing on machine learning and data science in the field of glycobiology. He obtained his Ph.D. in mammalian synthetic biology at ETH Zurich and continued his postdoctoral training in computational biology at MIT & Harvard University. His group develops and applies methods to discover sequence-to-function associations and biological roles of glycans via a broad set of approaches from machine learning, data science, and bioinformatics. Daniel was awarded a Branco Weiss Fellowship - Society in Science, as well as a Foresight Fellowship, and was recognized as a "Rising Star" by the journal Advanced Science. He was also featured on the 2022 Forbes 30 Under 30 Europe list for work in Science & Healthcare.
Title: C-Mannosylation of Proteins: Specificity and Function
Dr. Hans Bakker is a glycobiologist with expertise in glycosyltransferases. He received his Ph.D. at the VU Amsterdam, the Netherlands, and worked in Zurich, Switzerland, and Wageningen, the Netherlands, afterwards. Since 2001, he has worked at Hannover Medical School in Germany. Over the years, he has identified several new genes encoding glycosyltransferases, including the xylosyltransferases responsible for the glycosylation of Notch EGF repeats and, more recently, the first C-mannosyltransferase, the enzyme responsible for unique glycosylation of tryptophans in proteins. His laboratory has established several specific methods to characterize C-mannosyltransferases and their target proteins from Caenorhabditis elegans and mammals in vitro and cellular systems. After cloning the C-mannosyltransferase in 2013, he could establish that C-mannosylation assists in protein folding in the endoplasmic reticulum and is important for the temperature stability of proteins. Whereas C. elegans has one C- mannosyltransferase, four homologs are present in mammals. His group could show that different mammalian C-mannosyltransferases have distinct fine specificity.
Title: Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Dr. Vered Padler-Karavani received her PhD in biochemistry from Tel Aviv University. She then did her postdoctoral training with Prof. Ajit Varki at The University of California, San Diego (UCSD) and subsequently established The Laboratory for Glycoimmunology at Tel Aviv University The George S. Wise Faculty of Life Sciences, Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research. Her research combines glycobiology, immunology, bio-nanotechnology, cancer research and xenotransplantation, and involves cutting edge technologies within these disciplines. She received several prestigious grants from the European Commission (Marie Curie, Health Consortium, ERC) to investigate various aspects of immunology of carbohydrates. With TRANSLINK health consortium (6 academic institutes, 5 hospitals and 3 companies from Israel, Italy, France, Spain, UK, Sweden, Canada and USA; https://cordis.europa.eu/project/id/603049), she investigated risk factors of animal-derived heart valve implants, in ~5,000 patients. Her research is currently focused on studying mechanisms of glycan immune recognition and responses in animal models and in humans, in vitro and in vivo. Particularly, the immunological basis of anti-carbohydrate antibodies and their implications on cancer and heart diseases, and on developing novel diagnostics and therapeutics for such diseases.
Dr. Linda Hsieh-Wilson is a Professor of Chemistry at the California Institute of Technology. She was born in New York City and obtained her B.S. degree magna cum laude in chemistry from Yale University in 1990. In 1996, she received her Ph.D. in chemistry from the University of California at Berkeley, where she was a National Science Foundation predoctoral fellow in the laboratory of Professor Peter Schultz. In 1996, she moved to Rockefeller University to study neurobiology with Professor and Nobel Laureate Paul Greengard as a Damon Runyon-Walter Winchell postdoctoral fellow. Hsieh-Wilson joined the faculty at the California Institute of Technology in 2000, where she became an associate professor of chemistry in 2006 and a full professor in 2010. She was an Investigator at the Howard Hughes Medical Institute from 2005-2014, and in 2015, she was elected to the American Academy of Arts and Sciences.
Professor Hsieh-Wilson has pioneered the application of organic chemistry to understand the roles of carbohydrates and protein glycosylation in neurobiology. Her honors include a Beckman Young Investigator Award (2000), Research Corporation Research Innovation Award (2000), Alfred P. Sloan Fellowship (2003), Eli Lilly Award in Biological Chemistry (2006), Arthur C. Cope Scholar Award (2008), Gill Young Investigator Award in Neuroscience (2009), and Horace S. Isbell Award in Carbohydrate Chemistry (2014).
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.
Title: Glycosyl Hydrolases from the Seeds of Cucurbitaceae
Professor Nadimpalli is a Senior Professor in Biochemistry at University of Hyderabad, Hyderabad, India. He did his postdoctoral training at DAAD, Wuerzburg and Goettingen, Germany, and has been a faculty at University of Hyderabad since 1986.
His glyco-related contributions include development of novel affinity methods to purify mannose 6-phosphate receptors, discovery of LERP from Drosophila and lysosomal enzymes and their receptors in Hydra. He also identified and purified several plant and animal glycosidases, contributed towards understanding the physiological significance of Cucurbitaceae seed lectins and glycosidases.
His Research Interests are (1) Evolution of lysosomal biogenesis; (2) Legume and non-legume lectins-structure-function relationships; (3) Physiological functions of Plant lectins and glycosidases from legumes and non-legumes.
Title: Systems Level Studies of Viral Infection: Roles for Site-specific Glycosylation, Biochemical Pathways and Intracellular Lectins
Dr. Sriram Neelamegham is a UB Distinguished Professor of Chemical & Biological Engineering, Biomedical Engineering, and Medicine at the State University of New York-Buffalo. His laboratory works at the interface of engineering and medicine, with applications in studies of human disease mechanics. Such work falls under the umbrella of "Systems Glycobiology," where high-throughput experimentation and mathematical modeling are coupled to describe the interplay between the competing glycoEnzymes that regulate cellular glycosylation patterns. Prof. Neelamegham has published over 140 research articles, book chapters, and patents. He receives the NIH Independent Scientist award, the 2015 State University of New York Chancellor's Award for Excellence in Scholarship and Creative Activities, and the 2018 Schoellkopf medal from the Western New York American Chemical Society. He is an Elected Fellow of the American Institute of Biological and Medical Engineering (AIMBE) and Biomedical Engineering Society (BMES). He has served on NIH advisory panels and editorial boards of various journals. He is currently the Discussion Leader developing the Symbol Nomenclature for Glycans (SNFG) at the NCBI-glycans resource. Before moving to Buffalo. Prof. Neelamegham received his Ph.D. in Chemical Engineering/Bioengineering from the Rice University and completed his post-doctoral training at the Baylor College of Medicine.
Title: Cell-based Mucin Array for Discovery and Characterization of Mucinase and Glycan-Binding Modules.
Dr. Narimatsu is an Associate Professor at Copenhagen Center for Glycomics, Ph.D. (2008, Tsukuba University, Japan). His study focuses on the structure, biosynthesis, and genetic regulation of complex carbohydrates. He received training for eight years at the glycobiology lab, Research Center for Medical Glycoscience (RCMG) in Japan. Joined a Center of Excellence in Glycomics funded by the Danish National Research Foundation at the University of Copenhagen in 2012 and contributed to developing a comprehensive and high-throughput platform for CRISPR/Cas9 gene targeting of the human glycome (GlycoCRISPR), a large library of glycoengineered cells (GlycoDisplay), a cell-based platform for the display and production of human Mucin tandem repeat (MucinDisplay). His research interests include a basic understanding of genetic regulation and biosynthesis of protein glycosylation, consequences of deficiencies in glycosylation in diseases, and biomedical applications.
His group has taken a global "glycogenome" engineering approach to protein glycosylation and proposed a Cell-Based glycan array platform to display the human glycome–i.e., display of all human glycans on proteins, proteoglycans, and lipids. This self-renewable array is useful for discovering biological interactions involving glycans, and screening of true high-affinity interactions with glycans requires the natural biological context of specific proteins and cell surfaces.